Phys Vivas · rheumatological
Immunological Investigation Immunoglobulins Complement Flow Cytometry — Viva Defence
DCE viva defence for Immunological Investigation Immunoglobulins Complement Flow Cytometry.
On this page
Study tools
Target exams
Immunological Investigation Immunoglobulins Complement Flow Cytometry Viva
Long Case Viva Defence
Opening statement
"This patient presents with a problem best framed as Immunological Investigation Immunoglobulins Complement Flow Cytometry. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up."
Examiner questions
Q1: "What makes this urgent?"
"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up."
Q2: "What is your first investigation package?"
"I order tests that change management now, not a scattergun panel."
Q3: "Walk me through treatment."
"Stabilise, treat the mechanism, prevent complications, and plan monitoring."
Q4: "What is the classic trap?"
"Treating a label without confirming the discriminating mechanism, or delaying escalation."
References5ShowHide
- [1]Seitz M, Villiger P [Value of laboratory diagnosis in inflammatory rheumatologic diseases] Praxis (Bern 1994), 2002.PMID 11845615
- [5]Ye S, Li D, Liu F, Lei M, et al. In vitro evaluation of the biological activities of IgG in seven Chinese intravenous immunoglobulin preparations J Pharm Biomed Anal, 2018.PMID 29413980
- [6]Barth MJ, Mavis C, Czuczman MS, Hernandez-Ilizaliturri FJ Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma Clin Cancer Res, 2015.PMID 25964296
- [7]Barsalou J, Saint-Cyr C, Drouin E, Le Deist F, et al. High prevalence of primary immune deficiencies in children with autoimmune disorders Clin Exp Rheumatol, 2011.PMID 21345299
- [8]Dialynas DP, Wilde DB, Marrack P, Pierres A, et al. Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity Immunol Rev, 1983.PMID 6195085